Pharmacokinetics and Antihypertensive Effects of Candesartan Cilexetil in Patients Undergoing HaemodialysisAn Open-Label, Single-Centre Study

被引：0
|
作者：
Egbert G. Schulz
Shadfar Bahri
Volker Schettler
Aron-Frederik Popov
Matthias Hermann
机构：
[1] Centre of Nephrology Goettingen,Department of Thoracic Cardiovascular Surgery
[2] University of Goettingen,Department of Cardiology
[3] University Hospital Zurich,undefined
来源：
Clinical Drug Investigation | 2009年 / 29卷
关键词：
Candesartan; Aliskiren; Endstage Renal Failure; Candesartan Cilexetil; Anuric Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background and Objective: In patients with endstage renal failure (ERF), activation of the renin-angiotensin-aldosterone system plays an important role in the onset and maintenance of arterial hypertension. This study aimed to elucidate the antihypertensive effect, pharmacokinetics and safety of candesartan cilexetil in patients with ERF undergoing haemodialysis.
引用
收藏
页码：713 / 719
页数：6
相关论文
共 50 条
  • [41] Protocol for evaluating the effects of the Reducing Cardiometabolic Diseases Risk dietary pattern in the Chinese population with dyslipidaemia: a single-centre, open-label, dietary intervention study
    Wu, Qi
    Zhang, Liyang
    Cheng, Cheng
    Chen, Xukun
    Bian, Shanshan
    Huang, Li
    Li, Tongtong
    Li, Zhenshu
    Liu, Huan
    Yan, Jing
    Du, Yue
    Chen, Yongjie
    Zhang, Meilin
    Cao, Lichun
    Li, Wen
    Ma, Fei
    Huang, Guowei
    BMJ OPEN, 2024, 14 (04):
  • [42] Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study
    Matza, Mark A.
    Perugino, Cory A.
    Harvey, Liam
    Fernandes, Ana D.
    Wallace, Zachary S.
    Liu, Hang
    Allard-Chamard, Hugues
    Pillai, Shiv
    Stone, John H.
    LANCET RHEUMATOLOGY, 2022, 4 (02): : E105 - E112
  • [43] An Open-Label Safety and Pharmacokinetics Study of Duloxetine in Pediatric Patients with Major Depression
    Prakash, Apurva
    Lobo, Evelyn
    Kratochvil, Christopher J.
    Tamura, Roy N.
    Pangallo, Beth A.
    Bullok, Kristin E.
    Quinlan, Tonya
    Emslie, Graham J.
    March, John S.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2012, 22 (01) : 48 - 55
  • [44] Pharmacokinetics and Safety of Esketamine in Chinese Patients Undergoing Painless Gastroscopy in Comparison with Ketamine: A Randomized, Open-Label Clinical Study
    Wang, Jing
    Huang, Jie
    Yang, Shuang
    Cui, Chang
    Ye, Ling
    Wang, Sai-ying
    Yang, Guo-ping
    Pei, Qi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 4135 - 4144
  • [45] Effects of Hepatic Impairment on the Pharmacokinetics of Nilotinib: An Open-Label, Single-Dose, Parallel-Group Study
    Yin, Ophelia Q. P.
    Gallagher, Neil
    Tanaka, Chiaki
    Fisher, Deirdre
    Sethuraman, Venkat
    Zhou, Wei
    Lin, Tsu-Han
    Heuman, Douglas
    Schran, Horst
    CLINICAL THERAPEUTICS, 2009, 31 : 2459 - 2469
  • [46] Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
    Peveling-Oberhag, Jan
    Zeuzem, Stefan
    Yong, Wei Peng
    Kunz, Tiffany
    Paquet, Thierry
    Bouillaud, Emmanuel
    Urva, Shweta
    Anak, Oezlem
    Sellami, Dalila
    Kobalava, Zhanna
    CLINICAL THERAPEUTICS, 2013, 35 (03) : 215 - 225
  • [47] Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
    Wiebe, Sabrina
    Schnell, David
    Kuelzer, Raimund
    Gansser, Dietmar
    Weber, Anne
    Wallenstein, Gudrun
    Halabi, Atef
    Conrad, Anja
    Wind, Sven
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (03) : 461 - 469
  • [48] Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy Subjects A Single-Sequence, Open-Label Study
    Harrison, Brooke
    Magee, Mindy H.
    Mandagere, Arun
    Walker, Gennyne
    Dufton, Christopher
    Henderson, Linda S.
    Boinpally, Ramesh
    CLINICAL DRUG INVESTIGATION, 2010, 30 (12) : 875 - 885
  • [49] Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy SubjectsA Single-Sequence, Open-Label Study
    Brooke Harrison
    Mindy H. Magee
    Arun Mandagere
    Gennyne Walker
    Christopher Dufton
    Linda S. Henderson
    Ramesh Boinpally
    Clinical Drug Investigation, 2010, 30 : 875 - 885
  • [50] Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
    Sabrina Wiebe
    David Schnell
    Raimund Külzer
    Dietmar Gansser
    Anne Weber
    Gudrun Wallenstein
    Atef Halabi
    Anja Conrad
    Sven Wind
    European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42 : 461 - 469
12345